Company news

Revolution Medicines, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress

August 10, 2021

Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021

August 3, 2021

Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1

June 23, 2021

Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors

June 9, 2021

Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

June 1, 2021

Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit

May 17, 2021

Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress

May 9, 2021

Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting

May 2, 2021

Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors

April 20, 2021

Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021

March 10, 2021

Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress

March 1, 2021

Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences

February 17, 2021

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

February 7, 2021

Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock

February 2, 2021

Revolution Medicines Announces Proposed Public Offering of Common Stock

January 31, 2021

Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference

January 4, 2021

Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress

November 11, 2020

Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers

October 23, 2020

Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors

October 11, 2020

Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors

September 15, 2020

Revolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

September 8, 2020

Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference

September 7, 2020

← Newer news releases

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.